Scarica l'app Stockscreener
39.31
0.65%
-0.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$39.60
Aprire:
$39.5
Volume 24 ore:
1.01M
Relative Volume:
0.24
Capitalizzazione di mercato:
$16.80B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
17.11
EPS:
2.297
Flusso di cassa netto:
$827.02M
1 W Prestazione:
-1.25%
1M Prestazione:
+3.97%
6M Prestazione:
+17.65%
1 anno Prestazione:
+50.73%
Intervallo 1D:
$39.24
$39.64
Intervallo di 1 settimana:
$39.24
$40.50
Portata 52W:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
39.33 | 16.92B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.23 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.53 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.88 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
919.90 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.52 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - MarketScreener
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com India
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser
Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com South Africa
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com South Africa
Transcript : Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03 - MarketScreener
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million - Investing.com
100,000 Shares in Royalty Pharma PLC $RPRX Acquired by Watchtower Advisors LP - MarketBeat
Norges Bank Invests $181.39 Million in Royalty Pharma PLC $RPRX - MarketBeat
Korea Investment CORP Sells 160,900 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock a good choice for value investorsTrade Signal Summary & Daily Momentum Trading Reports - Newser
How Royalty Pharma plc (RPD) stock correlates with oil marketsWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser
Royalty Pharma PLC $RPRX Shares Purchased by River Road Asset Management LLC - MarketBeat
Why Royalty Pharma plc (RPD) stock could break out in 2025July 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
Will Royalty Pharma plc (RPD) stock maintain strong growthQuarterly Earnings Report & Risk Managed Investment Strategies - Newser
Technical Reactions to RPRX Trends in Macro Strategies - news.stocktradersdaily.com
Royalty Pharma PLC $RPRX Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Elo Mutual Pension Insurance Co - MarketBeat
Patient Capital Management LLC Buys 15,342 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Northwest & Ethical Investments L.P. Takes $1.67 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Sells 286,493 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Franklin Resources Inc. Buys 151,248 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Insider Sold Shares Worth $2,682,505, According to a Recent SEC Filing - MarketScreener
Creative Planning Buys 9,718 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Is Royalty Pharma PLC Gaining or Losing Market Support? - Benzinga
Rhenman & Partners Asset Management AB Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $2.68 million in shares By Investing.com - Investing.com South Africa
Royalty Pharma EVP Coyne sells $2.68 million in shares - Investing.com
RPRX CFO Terrance P. Coyne reports 10b5-1 share sales - Stock Titan
Swiss National Bank Purchases 50,100 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - Enidnews.com
Legal & General Group Plc Has $97.97 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Vestor Capital LLC Sells 399,100 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc : Technically solid - MarketScreener
Handelsbanken Fonder AB Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Horizon Kinetics Asset Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Mediolanum International Funds Ltd Has $2.01 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
DNB Asset Management AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Shareholder TPC RP 2021 LLC Files To Sell 65,832 Of Royalty Pharma PLC [RPRX] - TradingView
Vanguard Group Inc. Trims Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Sierra Summit Advisors LLC Buys Shares of 19,360 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Royalty Pharma Plc Azioni (RPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.93 |
23,333 |
931,633 |
183,334 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.90 |
18,242 |
727,856 |
25,640 |
1.29%
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):